<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-8909</journal-id>
<journal-title><![CDATA[Medicina crítica (Colegio Mexicano de Medicina Crítica)]]></journal-title>
<abbrev-journal-title><![CDATA[Med. crít. (Col. Mex. Med. Crít.)]]></abbrev-journal-title>
<issn>2448-8909</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Medicina Crítica A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-89092022000300142</article-id>
<article-id pub-id-type="doi">10.35366/105379</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Delta de ácido úrico como predictor de severidad en pacientes con SARS-CoV-2]]></article-title>
<article-title xml:lang="en"><![CDATA[Delta uric acid as a predicator of severity in patients with SARS-CoV-2]]></article-title>
<article-title xml:lang="pt"><![CDATA[Delta do ácido úrico como preditor de gravidade em pacientes com SARS-CoV-2]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Fernández]]></surname>
<given-names><![CDATA[Oyuky]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendoza Portillo]]></surname>
<given-names><![CDATA[Elizabeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendoza Rodríguez]]></surname>
<given-names><![CDATA[Martin]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Secretaría de Salud de la Ciudad de México Hospital General La Villa ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>36</volume>
<numero>3</numero>
<fpage>142</fpage>
<lpage>147</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-89092022000300142&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-89092022000300142&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-89092022000300142&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  El SARS-CoV-2 representa la primera causa de mortalidad actual en la población mexicana, a nivel global se han acumulado 1&#8217;919,126 defunciones. Las regiones con más muertes son América (47%) y Europa (33%). Hasta la semana 2 del año 2021 en México se estimaban 1&#8217;541,633 casos, siendo la Ciudad de México la entidad más afectada; hasta ese momento se habían registrado 18,443 fallecimientos, con una necesidad hospitalaria de 80% y con alta demanda de hospitalización en el servicio de Unidad de Cuidados Intensivos (UCI). Por esta razón, surge la necesidad de nuevos marcadores tempranos de severidad y pronóstico.  Objetivo:  Correlacionar el delta de ácido úrico (DAU) con la mortalidad en pacientes con SARS-CoV-2 tratados en la UCI, así como su relación con otras variables de severidad.  Material y métodos:  Se realizó un estudio longitudinal en una UCI con 71 pacientes; las variables de estudio fueron: demográficas, comorbilidades, días de estancia en la UCI, días de ventilación mecánica (VM), escala predictora de mortalidad, ácido úrico inicial y ácido úrico final, DAU; desenlace: mortalidad.  Resultados:  De los participantes, 69% fueron varones, 31% mujeres, edad promedio de 54.35 años (± 10.28), ácido úrico al ingreso de 3.9 mg/dL (± 1.74), ácido úrico al egreso de 2.89 mg/dL (± 1.70), delta de ácido úrico promedio de 1.077 mg/dL (± 1.59), APACHE II al ingreso de 18.35 puntos (± 9.04) y al egreso de 22.95 puntos (± 19.68), mortalidad global de 50.7%, de los cuales 78.67% requirió ventilación mecánica y 21.12% no la requirió. La correlación de Spearman para DAU y mortalidad fue r = -0.34, el índice de determinación r2 = 0.13, con significancia p = 0.004, (IC) 95%.  Conclusiones:  Se demostró la correlación entre el DAU con la mortalidad de los pacientes con SARS-CoV-2 con adecuada significancia estadística a un intervalo de corte de 1-1.5 mg/dL y una mortalidad de 50.7%. Adicionalmente, se demostró que dicho intervalo tuvo correlación con el inicio de la ventilación mecánica. Se identificó que sí existe relación entre la puntuación de APACHE II y la mortalidad por SARS-CoV-2; para este estudio un puntaje mayor a 18 demostró la mejor significancia estadística.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  SARS-CoV-2 represents the first cause of current mortality in the Mexican population, globally it has accumulated 1&#8217;919,126 deaths. The regions with the most deaths are America (47%), Europe (33%). Until week two of 2021 in Mexico, 1&#8217;541,633 cases were estimated, with Mexico City being the most affected entity, until that moment 18,443 deaths had been registered, with a hospital need of 80%, and with a high demand for hospitalization in the service of Intensive Care Unit (ICU). For this reason, the need arises for new early markers of severity and prognosis.  Objective:  To correlate the uric acid delta (DAU) with mortality in patients with SARS-CoV-2 treated in the ICU, as well as its relationship with other variables of severity.  Material and methods:  A longitudinal study was carried out in the ICU with 71 patients and study variables: demographic, comorbidities, days of ICU stay, days of mechanical ventilation (MV), predictive mortality scale, initial uric acid and final uric acid, DAU; outcome: mortality.  Results:  Of the participants, 69% were men, 31% women, mean age of 54.35 years (± 10.28), uric acid at admission of 3.9 mg/dL (± 1.74), uric acid at discharge of 2.89 mg/dL (± 1.70), mean uric acid delta of 1.077 mg/dL (± 1.59 mg/dL), APACHE II at entry of 18.35 points (± 9.04) at discharge of 22.95 points (± 19.68), global mortality of 50.7%, of which 78.67% required mechanical ventilation (MV) and 21.12% did not require. The Spearman correlation for DAU and mortality was r = -0.34, the determination index r2 = 0.13, with significance p = 0.004, (CI) 95%.  Conclusions:  The correlation between the DAU with the mortality of the patients with SARS-CoV-2 was demonstrated with adequate statistical significance at a cut-off interval of 1-1.5 mg/dL, and a mortality of 50.7%. Additionally, it was shown that said interval had a correlation with the start of mechanical ventilation. It was identified that if there is a relationship between the APACHE II score and SARS-CoV-2 mortality, for this study a score greater than 18 demonstrated the best statistical significance.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução:  O SARS-CoV-2 representa a primeira causa de mortalidade atual na população mexicana, globalmente acumulou 1.919.126 mortes. As regiões com mais mortes são América (47%), Europa (33%). Até a semana 2 de 2021 no México, foram estimados 1.541.633 casos, sendo a Cidade do México a entidade mais afetada, até então foram registrados 18.443 óbitos, com necessidade hospitalar de 80% e com alta demanda de internação no serviço de emergência Unidade de Terapia Intensiva (UTI). Por esta razão, há necessidade de novos marcadores precoces de gravidade e prognóstico.  Objetivo:  Correlacionar o delta do ácido úrico (DAC) com a mortalidade em pacientes com SARS-CoV-2 atendidos na UTI, bem como sua relação com outras variáveis de gravidade.  Material e métodos:  Realizou-se um estudo longitudinal na UTI com 71 pacientes e variáveis de estudo: demografia, comorbidades, dias de internação na UTI, dias de ventilação mecânica (VM), escala preditiva de mortalidade, ácido úrico inicial e ácido úrico final, DAC; resultado: mortalidade.  Resultados:  Dos participantes, 69% eram homens, 31% mulheres, idade média 54.35 anos (± 10.28), ácido úrico na admissão 3.9 mg/dL (± 1.74), ácido úrico na alta 2.89 mg/dL (± 1.70), delta de ácido úrico médio de 1.077 mg/dL (± 1.59 mg/dL), APACHE II na admissão de 18.35 pontos (± 9.04) na alta de 22.95 pontos (± 19.68), mortalidade geral de 50.7%, dos quais 78.67% necessitaram de ventilação mecânica (VM) e 21.12% não necessitaram. A correlação de Spearman para DAU e mortalidade foi r = -0.34, o índice de determinação r2 = 0.13, com significância p = 0.004, (IC) 95%.  Conclusões:  Demonstrou-se a correlação entre o DAU com a mortalidade de pacientes com SARS-CoV-2 com adequada significância estatística no intervalo de corte de 1-1.5 mg/dL e mortalidade de 50.7%. Além disso, foi demonstrado que esse intervalo se correlacionou com o início da ventilação mecânica. Identificou-se que existe relação entre o escore APACHE II e a mortalidade por SARS-CoV-2, para este estudo um escore maior que 18 apresentou a melhor significância estatística.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Delta de ácido úrico]]></kwd>
<kwd lng="es"><![CDATA[APACHE II]]></kwd>
<kwd lng="es"><![CDATA[mortalidad]]></kwd>
<kwd lng="es"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="es"><![CDATA[ventilación mecánica]]></kwd>
<kwd lng="en"><![CDATA[Uric acid delta]]></kwd>
<kwd lng="en"><![CDATA[APACHE II]]></kwd>
<kwd lng="en"><![CDATA[mortality]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="en"><![CDATA[mechanical ventilation]]></kwd>
<kwd lng="pt"><![CDATA[Delta do ácido úrico]]></kwd>
<kwd lng="pt"><![CDATA[APACHE II]]></kwd>
<kwd lng="pt"><![CDATA[mortalidade]]></kwd>
<kwd lng="pt"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="pt"><![CDATA[ventilação mecânica]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Secretaria de Salud</collab>
<source><![CDATA[2o Informe epidemiológico de la situación de Covid-19. Dirección de información epidemiológica]]></source>
<year>2021</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peralta-Prado]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Hinojosa]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Polo]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[López-Aguilar]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Maya-Romero]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Carrillo-Esper]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlación de la delta de ácido úrico con la gravedad de la sepsis]]></article-title>
<source><![CDATA[Med Int Mex]]></source>
<year>2016</year>
<volume>29</volume>
<page-range>154-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aminiahidashti]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bozorgi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mousavi]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sedighi]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Gorji]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Rashidian]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum uric acid level in relation to severity of the disease and mortality of critically ill patients]]></article-title>
<source><![CDATA[J Lab Physicians]]></source>
<year>2017</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>42-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhandary]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Shetty]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
<name>
<surname><![CDATA[Akshatha]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperuricemia as an early marker in predicting the mortality and morbidity in patients with sepsis]]></article-title>
<source><![CDATA[Int J Contemp Med Res]]></source>
<year>2019</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>2393-915</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suárez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Suarez Quezada]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Oros Ruiza]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ronquillo De Jesús]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología de COVID-19 en México: del 27 de febrero al 30 de abril de 2020]]></article-title>
<source><![CDATA[Rev Clin Esp]]></source>
<year>2020</year>
<volume>220</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>463-71</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum uric acid on admission cannot predict long-term outcome of critically ill patients: a retrospective cohort study]]></article-title>
<source><![CDATA[Ther Clin Risk Manag]]></source>
<year>2018</year>
<volume>14</volume>
<page-range>1347-59</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giovannini]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Chiarla]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Giuliante]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pallavicini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Vellone]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ardito]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum uric acid, creatinine, and the assessment of antioxidant capacity in critical illness]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2006</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>421</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of baseline APACHE II score combined with uric acid concentration for short-term clinical outcomes in patients with sepsis]]></article-title>
<source><![CDATA[All Life]]></source>
<year>2020</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>416-25</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pehlivanlar-Kucuk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kucuk]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
<name>
<surname><![CDATA[Ozturk]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Er]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Ulger]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association between serum uric acid level and prognosis in critically ill patients, uric acid as a prognosis predictor]]></article-title>
<source><![CDATA[Clin Lab]]></source>
<year>2018</year>
<volume>64</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1491-500</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Akbar]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Hussain]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Alhajhusain]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[US]]></given-names>
</name>
<name>
<surname><![CDATA[Iqbal]]></surname>
<given-names><![CDATA[HI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperuricemia: an early marker for severity of illness in sepsis]]></article-title>
<source><![CDATA[Int J Nephrol]]></source>
<year>2015</year>
<volume>2015</volume>
<page-range>301021</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hussain Bhat]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uric acid a predictor of sepsis in critically ill patients]]></article-title>
<source><![CDATA[J Adv Med Dental Sci Res]]></source>
<year>2018</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>158-61</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The relationship between serum levels of uric acid and prognosis of infection in critically ill patients]]></article-title>
<source><![CDATA[World J Emerg Med]]></source>
<year>2012</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>186-90</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuipers]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Aslami]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Van der Poll]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Schultz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wieland]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Danger signal uric acid is involved in ventilator-induced lung injury pathogenesis]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2011</year>
<volume>15</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>P192</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elshafey]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Abu Mossalam]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Makharita]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Elewa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic role of serum uric acid in acute respiratory distress syndrome patients: a preliminary study]]></article-title>
<source><![CDATA[Egypt J Chest Dis Tuberc]]></source>
<year>2015</year>
<volume>64</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>197-202</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuipers]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Aslami]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Vlaar]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Juffermans]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Tuip-de Boer]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Hegeman]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pre-treatment with allopurinol or uricase attenuates barrier dysfunction but not inflammation during murine ventilator-induced lung injury]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2012</year>
<volume>7</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghiselli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Serafini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Natella]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Capacidad antioxidante total como herramienta para evaluar el estado redox: vista crítica y datos experimentales]]></article-title>
<source><![CDATA[Free Rad Biol Med]]></source>
<year>2016</year>
<volume>29</volume>
<page-range>1106-11</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alcántara-Alonso]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Molinar-Ramos]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[González-López]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Alcántara-Alonso]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz-Pérez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano-Nuevo]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High triglyceride to HDL-cholesterol ratio as a biochemical marker of severe outcomes in COVID-19 patients]]></article-title>
<source><![CDATA[Clin Nutr ESPEN]]></source>
<year>2021</year>
<volume>44</volume>
<page-range>437-44</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dufour]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Werion]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Belkhir]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wisniewska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perrot]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Greef]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum uric acid, disease severity and outcomes in COVID-19]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2021</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>212</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
